UNSPSC 51182103: Conivaptan

This classification denotes a vasopressin antagonist with the molecular formula C32H26N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NJ98Y462X, chemically known as (1,1-biphenyl)-2-carboxamide, n-(4-(4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)- but generally known as conivaptan, which bears US NIH Compound Identifier 151171. European Medicines Agency schedules Conivaptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32706.

UNSPSC 51182103 Conivaptan, a Commodity code, encompasses pharmaceutical products supplied through multistate cooperative purchasing agreements to state and local government healthcare and facility networks. State and local procurement activity under this code focuses on establishing framework contracts for generic pharmaceuticals and over-the-counter products distributed to participating agencies through authorized drug wholesalers, with vendors required to supply specific National Drug Codes (NDCs) with detailed product specifications and comply with cGMP, FDA, and Drug Supply Chain Security Act (DSCSA) requirements. Issuing bodies include state departments of administration and multistate cooperative purchasing alliances that coordinate procurement across multiple participating jurisdictions, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering distribution to state and local facilities across multiple states including Oregon.

The most recent solicitation activity centers on the Minnesota Department of Administration's Office of State Procurement, which issued an RFP through MMCAP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and submit pricing in multiple formats including flat price, net price, or WAC-minus structures. Evaluation criteria emphasize price competitiveness at 75 percent weight, with the remaining 25 percent distributed across fixed pricing, administrative fee format compliance, EDI capability, and agreement to a 3 percent administrative fee. Awarded contracts are effective July 1, 2026, for two-year terms with optional extensions, and vendors must carry $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability insurance.